Evaluating Lipid‐Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization

Long‐term exposure to lipid‐lowering drugs might affect Parkinson's disease (PD) risk. We conducted Mendelian randomization analyses where genetic variants indexed expected effects of modulating lipid‐lowering drug targets on PD. Statin exposure was not predicted to increase PD risk, although r...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Dylan M., Bandres‐Ciga, Sara, Heilbron, Karl, Hinds, David, Noyce, Alastair J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693098/
https://www.ncbi.nlm.nih.gov/pubmed/32841444
http://dx.doi.org/10.1002/ana.25880
_version_ 1783614665829384192
author Williams, Dylan M.
Bandres‐Ciga, Sara
Heilbron, Karl
Hinds, David
Noyce, Alastair J.
author_facet Williams, Dylan M.
Bandres‐Ciga, Sara
Heilbron, Karl
Hinds, David
Noyce, Alastair J.
author_sort Williams, Dylan M.
collection PubMed
description Long‐term exposure to lipid‐lowering drugs might affect Parkinson's disease (PD) risk. We conducted Mendelian randomization analyses where genetic variants indexed expected effects of modulating lipid‐lowering drug targets on PD. Statin exposure was not predicted to increase PD risk, although results were not precise enough to support benefits for prevention clearly (odds ratio [OR] = 0.83; 95% confidence interval [CI] = 0.65, 1.07). Other target results were null, except for variants indicating Apolipoprotein‐A5 or Apolipoprotein‐C3 inhibition might confer protection. These findings suggest peripheral lipid variation may not have a prominent role in PD etiology, but some related drug targets could influence PD via alternate pathways. ANN NEUROL 2020;88:1043–1047
format Online
Article
Text
id pubmed-7693098
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-76930982020-12-11 Evaluating Lipid‐Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization Williams, Dylan M. Bandres‐Ciga, Sara Heilbron, Karl Hinds, David Noyce, Alastair J. Ann Neurol Brief Communications Long‐term exposure to lipid‐lowering drugs might affect Parkinson's disease (PD) risk. We conducted Mendelian randomization analyses where genetic variants indexed expected effects of modulating lipid‐lowering drug targets on PD. Statin exposure was not predicted to increase PD risk, although results were not precise enough to support benefits for prevention clearly (odds ratio [OR] = 0.83; 95% confidence interval [CI] = 0.65, 1.07). Other target results were null, except for variants indicating Apolipoprotein‐A5 or Apolipoprotein‐C3 inhibition might confer protection. These findings suggest peripheral lipid variation may not have a prominent role in PD etiology, but some related drug targets could influence PD via alternate pathways. ANN NEUROL 2020;88:1043–1047 John Wiley & Sons, Inc. 2020-09-07 2020-11 /pmc/articles/PMC7693098/ /pubmed/32841444 http://dx.doi.org/10.1002/ana.25880 Text en © 2020 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communications
Williams, Dylan M.
Bandres‐Ciga, Sara
Heilbron, Karl
Hinds, David
Noyce, Alastair J.
Evaluating Lipid‐Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization
title Evaluating Lipid‐Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization
title_full Evaluating Lipid‐Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization
title_fullStr Evaluating Lipid‐Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization
title_full_unstemmed Evaluating Lipid‐Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization
title_short Evaluating Lipid‐Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization
title_sort evaluating lipid‐lowering drug targets for parkinson's disease prevention with mendelian randomization
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693098/
https://www.ncbi.nlm.nih.gov/pubmed/32841444
http://dx.doi.org/10.1002/ana.25880
work_keys_str_mv AT williamsdylanm evaluatinglipidloweringdrugtargetsforparkinsonsdiseasepreventionwithmendelianrandomization
AT bandrescigasara evaluatinglipidloweringdrugtargetsforparkinsonsdiseasepreventionwithmendelianrandomization
AT heilbronkarl evaluatinglipidloweringdrugtargetsforparkinsonsdiseasepreventionwithmendelianrandomization
AT hindsdavid evaluatinglipidloweringdrugtargetsforparkinsonsdiseasepreventionwithmendelianrandomization
AT noycealastairj evaluatinglipidloweringdrugtargetsforparkinsonsdiseasepreventionwithmendelianrandomization
AT evaluatinglipidloweringdrugtargetsforparkinsonsdiseasepreventionwithmendelianrandomization
AT evaluatinglipidloweringdrugtargetsforparkinsonsdiseasepreventionwithmendelianrandomization

Ejemplares similares